#BEGIN_DRUGCARD DB01089

# AHFS_Codes:
Not Available

# ATC_Codes:
C02AA05

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Canescin
Canescine
Harmonyl
Raunorine
Raunormin
Raunormine
Recanescin
Recanescine
Reserpidine
Tranquinil

# CAS_Registry_Number:
131-01-1

# ChEBI_ID:
27478

# Chemical_Formula:
C32H38N2O8

# Chemical_IUPAC_Name:
methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior.

# Dosage_Forms:
Not Available

# Drug_Category:
Antihypertensive Agents

# Drug_Interactions:
Epinephrine	Increased arterial pressure
Fenoterol	Increased arterial pressure
Orciprenaline	Increased arterial pressure
Phenylephrine	Increased arterial pressure
Phenylpropanolamine	Increased arterial pressure
Pseudoephedrine	Increased arterial pressure
Terbutaline	Increased arterial pressure

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Deserpidine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1

# InChI_Key:
InChIKey=CVBMAZKKCSYWQR-WCGOZPBSSA-N

# Indication:
For the treatment of hypertension.

# KEGG_Compound_ID:
C06541

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1089

# Mechanism_Of_Action:
Deserpidine's mechanism of action is through inhibition of the ATP/Mg<sup>2+</sup> pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.

# Melting_Point:
230.5 Â°C

# Molecular_Weight_Avg:
578.6527

# Molecular_Weight_Mono:
578.262816202

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164742966

# Pharmacology:
Deserpidine, an alkaloid of <i>Rauwolfia canescens</i>, is used as an antihypertensive. Rauwolfia alkaloids work by controlling nerve impulses along certain nerve pathways. As a result, they act on the heart and blood vessels to lower blood pressure.

# Predicted_LogP_Hydrophobicity:
4.25

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
1.11e-02 g/l

# Primary_Accession_No:
DB01089

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
8550

# PubChem_Substance_ID:
46505311

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00906

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Deresperine
Desepridine
Deserpidin
Deserpidina [INN-Spanish]
Deserpidinum [INN-Latin]
Deserpine
Desmethoxyreserpine

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include dizziness or drowsiness (severe), flushing of skin, pinpoint pupils of eyes and slowed pulse.

# Update_Date:
2013-02-08 16:19:54 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic vesicle
cytoplasmic vesicle membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11134	Fulton SC, Healy MD: Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fed Proc. 1976 Dec;35(14):2558-62.
1438304	Erickson JD, Eiden LE, Hoffman BJ: Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7.
17559790	Sievert MK, Hajipour AR, Ruoho AE: Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Anal Biochem. 2007 Aug 1;367(1):68-78. Epub 2007 May 3.
20176067	Mandela P, Chandley M, Xu YY, Zhu MY, Ordway GA: Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem Int. 2010 May-Jun;56(6-7):760-7. Epub 2010 Feb 20.
574544	Loeffler LJ, Schran HF: Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay. J Pharm Sci. 1979 Nov;68(11):1433-5.
8525459	Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J: Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995 Sep;21(1):29-36.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SLC18A2

# Drug_Target_1_GenBank_ID_Gene:
L09118

# Drug_Target_1_GenBank_ID_Protein:
292335

# Drug_Target_1_GeneCard_ID:
SLC18A2

# Drug_Target_1_Gene_Name:
SLC18A2

# Drug_Target_1_Gene_Sequence:
>1545 bp
ATGGCCCTGAGCGAGCTGGCGCTGGTCCGCTGGCTGCAGGAGAGCCGCCGCTCGCGGAAG
CTCATCCTGTTCATCGTGTTCCTGGCGCTGCTGCTGGACAACATGCTGCTCACTGTCGTG
GTCCCCATCATCCCAAGTTATCTGTACAGCATTAAGCATGAGAAGAATGCTACAGAAATC
CAGACGGCCAGGCCAGTGCACACTGCCTCCATCTCAGACAGCTTCCAGAGCATCTTCTCC
TATTATGATAACTCGACTATGGTCACCGGGAATGCTACCAGAGACCTGACACTTCATCAG
ACCGCCACACAGCACATGGTGACCAACGCGTCCGCTGTTCCTTCCGACTGTCCCAGTGAA
GACAAAGACCTCCTGAATGAAAACGTGCAAGTTGGTCTGTTGTTTGCCTCGAAAGCCACC
GTCCAGCTCATCACCAACCCTTTCATAGGACTACTGACCAACAGAATTGGCTATCCAATT
CCCATATTTGCGGGATTCTGCATCATGTTTGTCTCAACAATTATGTTTGCCTTCTCCAGC
AGCTATGCCTTCCTGCTGATTGCCAGGTCGCTGCAGGGCATCGGCTCGTCCTGCTCCTCT
GTGGCTGGGATGGGCATGCTTGCCAGTGTCTACACAGATGATGAAGAGAGAGGCAACGTC
ATGGGAATCGCCTTGGGAGGCCTGGCCATGGGGGTCTTAGTGGGCCCCCCCTTCGGGAGT
GTGCTCTATGAGTTTGTGGGGAAGACGGCTCCGTTCCTGGTGCTGGCCGCCCTGGTACTC
TTGGATGGAGCTATTCAGCTCTTTGTGCTCCAGCCGTCCCGGGTGCAGCCAGAGAGTCAG
AAGGGGACACCCCTAACCACGCTGCTGAAGGACCCGTACATCCTCATTGCTGCAGGCTCC
ATCTCCTTTGCAAACATGGGCATCGCCATGCTGGAGCCAGCCCTGCCCATCTGGATGATG
GAGACCATGTGTTCCCGCAAGTGGCAGCTGGGCGTTGCCTTCTTGCCAGCTAGTATCTCT
TATCTCATTGGAACCAATATTTTTGGGATACTTGCACACACAATGGGGAGGTGGCTTTGT
GCTCTTCTGGGAATGATAATTGTTGGAGTCAGCATTTTATGTATTCCATTTCCAAAAAAC
ATTTATGGACTCATAGCTCCGAACTTTGGAGTTGGTTTTGCAAATGGAATGGTGGATTCG
TCAATGATGCCTATCATGGGCTACCTCGTAGACCTGCGGCACGTGTCCGTCTATGGGAGT
GTGTACGCCATTGCGGATGTGGCATTTTGTATGGGGTATGCTATAGGTCCTTCTGCTGGT
GGTGCTATTGCAAAGGCAATTGGATTTCCATGGCTCATGACAATTATTGGGATAATTGAT
ATTCTTTTTGCCCCTCTCTGCTTTTTTCTTCGAAGTCCACCTGCCAAAGAAGAAAAAATG
GCTATTCTCATGGATCACAACTGCCCTATTAAAACAAAAATGTACACTCAGAATAATATC
CAGTCATATCCGATAGGTGAAGATGAAGAATCTGAAAGTGACTGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
11443533	Kunugi H, Ishida S, Akahane A, Nanko S: Exon/intron boundaries, novel polymorphisms, and association analysis with schizophrenia of the human synaptic vesicle monoamine transporter (SVMT) gene. Mol Psychiatry. 2001 Jul;6(4):456-60.
12009896	Thiriot DS, Sievert MK, Ruoho AE: Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. Biochemistry. 2002 May 21;41(20):6346-53.
8095030	Surratt CK, Persico AM, Yang XD, Edgar SR, Bird GS, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR: A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS Lett. 1993 Mar 8;318(3):325-30.
8245983	Erickson JD, Eiden LE: Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem. 1993 Dec;61(6):2314-7.

# Drug_Target_1_HGNC_ID:
HGNC:10935

# Drug_Target_1_HPRD_ID:
01896

# Drug_Target_1_ID:
131

# Drug_Target_1_Locus:
10q25

# Drug_Target_1_Molecular_Weight:
55714

# Drug_Target_1_Name:
Synaptic vesicular amine transporter

# Drug_Target_1_Number_of_Residues:
514

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07690	MFS_1

# Drug_Target_1_Protein_Sequence:
>Synaptic vesicular amine transporter
MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNATEI
QTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSE
DKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSS
SYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGS
VLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGS
ICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLC
ALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGS
VYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKM
AILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis

# Drug_Target_1_SwissProt_ID:
Q05940

# Drug_Target_1_SwissProt_Name:
VMAT2_HUMAN

# Drug_Target_1_Synonyms:
Monoamine transporter
Solute carrier family 18 member 2
VAT2
Vesicular amine transporter 2

# Drug_Target_1_Theoretical_pI:
5.91

# Drug_Target_1_Transmembrane_Regions:
21-41
130-150
160-180
190-210
220-242
249-271
292-311
329-352
358-378
390-410
415-435
441-462

#END_DRUGCARD DB01089
